Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
出版年份 2020 全文链接
标题
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
作者
关键词
-
出版物
Cancers
Volume 12, Issue 2, Pages 473
出版商
MDPI AG
发表日期
2020-02-24
DOI
10.3390/cancers12020473
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Breast cancer cell-derived soluble CD44 promotes tumor progression by triggering macrophage IL-1β production
- (2020) Jeong-Hoon Jang et al. CANCER RESEARCH
- Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
- (2019) Luigi Cavanna et al. Oncotarget
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
- (2019) Gaëlle Noé et al. Cancers
- The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer
- (2019) Taher Abu Hejleh et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
- (2018) MARIA BASSANELLI et al. ANTICANCER RESEARCH
- Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
- (2018) Masahiro Takeuchi et al. IMMUNOLOGY LETTERS
- Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
- (2018) Adrien Costantini et al. OncoImmunology
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
- (2018) Muhammad Khan et al. MEDICINE
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis
- (2018) Marcelo Bonomi et al. Oncology Letters
- Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients
- (2017) Alicja Puszkiel et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
- (2017) Shuguang Tan et al. Nature Communications
- Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
- (2017) Xinxin Zhu et al. Oncotarget
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
- (2017) Minghui Zhang et al. Scientific Reports
- Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
- (2016) Francesca Tartari et al. CANCER TREATMENT REVIEWS
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins
- (2016) Fabian Higel et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
- (2016) Naoki Takahashi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib
- (2016) Steffen Filskov Sorensen et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational signatures associated with tobacco smoking in human cancer
- (2016) L. B. Alexandrov et al. SCIENCE
- Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
- (2016) Hyerim Ha et al. Oncotarget
- Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
- (2016) Yu-Ling Li et al. Cancer Biology & Medicine
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer
- (2015) Yaxiong Zhang et al. MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
- (2015) Yanna Tang et al. Oncotarget
- Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
- (2015) Jie Zhang et al. Thoracic Cancer
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma
- (2014) Hye Chung et al. Journal of Translational Medicine
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma
- (2014) Hsiang-Yun Cheng et al. PLoS One
- Reconstructed Adeno-Associated Virus with the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity
- (2013) Osama A.O. Elhag et al. Asian Pacific Journal of Cancer Prevention
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- High circulating VEGF level predicts poor overall survival in lung cancer
- (2013) Pingping Hu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis
- (2013) SR Greisen et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- The role of soluble CD40L in immunosuppression
- (2013) Jeffrey Schlom et al. OncoImmunology
- Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role
- (2012) J. Huang et al. BLOOD
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Soluble B7-H1: Differences in production between dendritic cells and T cells
- (2011) Xavier Frigola et al. IMMUNOLOGY LETTERS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started